⌘K

Login Start Free

Home/Filings/4/0000875320-25-000234

4//SEC Filing

LEIDEN JEFFREY M 4

Accession 0000875320-25-000234

CIK 0000875320other

View on SEC.gov Company Profile

Filed

Nov 16, 7:00 PM ET

Accepted

Nov 17, 4:12 PM ET

Size

22.3 KB

Accession

0000875320-25-000234

Insider Transaction Report

Form 4

Period: 2025-11-13

VERTEX PHARMACEUTICALS INC / MAVRTX

LEIDEN JEFFREY M

Director

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2025-11-13−19,688→ 13,836 total
Exercise: $91.05Exp: 2026-02-01→ Common Stock (19,688 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-14−39,769→ 63,781 total
Exercise: $86.52Exp: 2027-02-02→ Common Stock (39,769 underlying)
Exercise/Conversion
Common Stock
2025-11-13$91.05/sh+19,688$1,792,592→ 43,714 total
Sale
Common Stock
2025-11-13$440.22/sh−18,528$8,156,396→ 25,186 total
Sale
Common Stock
2025-11-13$441.05/sh−1,160$511,618→ 24,026 total
Exercise/Conversion
Common Stock
2025-11-14$91.05/sh+13,835$1,259,677→ 37,861 total
Exercise/Conversion
Common Stock
2025-11-14$86.52/sh+39,769$3,440,814→ 77,630 total
Sale
Common Stock
2025-11-14$440.30/sh−32,234$14,192,630→ 45,396 total
Sale
Common Stock
2025-11-14$441.35/sh−21,330$9,413,996→ 24,066 total
Sale
Common Stock
2025-11-14$442.00/sh−40$17,680→ 24,026 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-14−13,835→ 1 total
Exercise: $91.05Exp: 2026-02-01→ Common Stock (13,835 underlying)

Holdings

Common Stock
(indirect: By 401(k))
440

Footnotes (7)

[F1]Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.
[F2]Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
[F3]Open market sales reported on this line occurred at a weighted average price of $440.22 (range $440.00 to $440.99).
[F4]Open market sales reported on this line occurred at a weighted average price of $441.05 (range $441.00 to $441.10).
[F5]Open market sales reported on this line occurred at a weighted average price of $440.30 (range $440.00 to $440.99).
[F6]Open market sales reported on this line occurred at a weighted average price of $441.35 (range $441.00 to $441.99).
[F7]Fully vested.

Documents

1 file

4
wk-form4_1763413922.xmlPrimary
FORM 4

Issuer

VERTEX PHARMACEUTICALS INC / MA

CIK 0000875320

Entity typeother

Related Parties

1

filerCIK 0001242825

Filing Metadata

Form type: 4
Filed: Nov 16, 7:00 PM ET
Accepted: Nov 17, 4:12 PM ET
Size: 22.3 KB

View on SEC.gov